Aim: This study focused on the impact of the clinical features on the quality of life (QoL) of Parkinson's disease (PD) patients and of their caregivers. Methods: This study included PD patients along with their caregivers and was undertaken at the Malaysian Parkinson's Disease Association from June 2016 to November 2016. Clinical features of PD patients were assessed using the Movement Disorder Society revised Unified Parkinson Disease Rating Scale; the Hoehn and Yahr stage and the Schwab and England Activities of Daily Living Scale were used to assess the severity and the ability of PD patients respectively. QoL of PD patients was measured using the Parkinson's Disease Questionnaire-39 (PDQ-39). The revised version of the Zarit Burden Interview assessed caregiver burden. Results: At least one of the clinical features affected PD patients' QoL, and at least one of the QoL domains affected the caregivers' burden. Clinical features “saliva and drooling” and “dyskinesia” explained 29% of variance in QoL of PD patients. The QoL domains “stigma,” along with “emotional well-being” explained 48.6% of variance in caregivers' burden. Conclusions: The clinical features “saliva and drooling” and “dyskinesia” impacted the QoL of PD patients, and the QoL domains “stigma” and “emotional well-being” of PD patients impacted their caregivers' burden.

Keywords:
Malaysia, Quality of life, Clinical features, Correlations, Carers
1.
Kalia LV, Lang AE: Parkinson's disease. Lancet 2015;386:896-912. DOI: 10.1016/s0140-6736(14)61393-3.
2.
Fernandez HH: Nonmotor complications of Parkinson disease. Cleve Clin J Med 2012;79(suppl 2):S14-S18. DOI: 10.3949/ccjm.79.s2a.03.
3.
Rahman S, Griffin HJ, Quinn NP, Jahanshahi M: Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008;23:1428-1434. DOI: 10.1002/mds.21667.
4.
Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, Mochizuki H, Hattori N, Mori H, Mizuno Y; Juntendo Parkinson Study Group: Prognosis of Parkinsonʼs disease: Time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006;21:1384-1395. DOI: 10.1002/mds.20993.
5.
Greenwell K, Gray WK, van Wersch A, van Schaik P, Walker R: Predictors of the psychosocial impact of being a carer of people living with Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2015;21:1-11. DOI: 10.1016/j.parkreldis.2014.10.013.
6.
Calabrese VP: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;69:223-224; author reply 224. DOI: 10.1212/01.wnl.0000271777.50910.73.
7.
Grün D, Pieri V, Vaillant M, Diederich NJ: Contributory factors to caregiver burden in Parkinson disease. J Am Med Dir Assoc 2016;17:626-632. DOI: 10.1016/j.jamda.2016.03.004.
8.
Goetz C: Unified Parkinson's Disease Rating Scale (UPDRS) and The Movement-Disorder Society Sponsored-unified Parkinson's disease Rating Scale (MDS-UPDRS). Encyclopedia Mov Disord 2010;307-309. DOI: 10.1016/b978-0-12-374105-9.00091-5.
9.
Poewe W: Global scales to stage disability in PD: the Hoehn and Yahr scale. Rating Scales Parkinsons Dis 2012;115-122. DOI: 10.1093/med/9780199783106.003.0258.
10.
Siderowf A: Schwab and England activities of daily living scale. Encyclopedia Mov Disord 2010;99-100. DOI: 10.1016/b978-0-12-374105-9.00070-8.
11.
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N: The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-357. DOI: 10.1093/ageing/26.5.353.
12.
Yiengprugsawan V: Caregiver Burden Scale: Zarit interview. Encyclopedia of Quality of Life and Well-Being Research 2014;566-567. DOI: 10.1007/978-94-007-0753-5_281.
13.
Rabey JM: Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord 2009;15. DOI: 10.1016/s1353-8020 (09)70846-6.
14.
Karbozova K: The study of the prevalence of Parkinson disease. Parkinsonism Relat Disord 2016;22. DOI: 10.1016/j.parkreldis.2015.10.023.
15.
Blackett H, Walker R, Wood B: Urinary dysfunction in Parkinson's disease: a review. Parkinsonism Relat Disord 2009;15:81-87. DOI: 10.1016/j.parkreldis.2007.10.016.
16.
Srivanitchapoom P, Pandey S, Hallett M: Drooling in Parkinson's disease: a review. Parkinsonism Relat Disord 2014;20:1109-1118. DOI: 10.1016/j.parkreldis.2014.08.013.
17.
Scalzo PL, Flores CR, Marques JR, Robini SC, Teixeira AL: Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson's disease. Arquivos Neuropsiquiatr 2012;70:119-124. DOI: 10.1590/s0004-282x2012000200009.
18.
Yousefi B, Tadibi V, Khoei AF, Montazeri A: Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. Trials 2009;10. DOI: 10.1186/1745-6215-10-67.
19.
Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Rascol O: Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol 2014;71:884. DOI: 10.1001/jamaneurol.2014.753.
20.
Hechtner MC, Vogt T, Zöllner Y, Schröder S, Sauer JB, Binder H, Mikolajczyk R: Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 2014;20:969-974. DOI: 10.1016/j.parkreldis.2014.06.001.
21.
Santos-García D, Fuente-Fernández RD: Factors contributing to caregivers' stress and burden in Parkinson's disease. Acta Neurol Scand 2014;131:203-210. DOI: 10.1111/ane.12305.
22.
Maffoni M, Giardini A, Pierobon A, Ferrazzoli D, Frazzitta G: Stigma experienced by Parkinsonʼs disease patients a descriptive review of qualitative studies. Parkinsons Dis 2017;1-7. DOI: 10.1155/2017/7203259.
23.
Sunvisson H, Ekman S: Environmental influences on the experiences of people with Parkinson's disease. Nursing Inquiry 2001;8:41-50. DOI: 10.1046/j.1440-1800.2001.00089.x.
24.
Lokk J, Delbari A: Clinical aspects of palliative care in advanced Parkinson's disease. BMC Palliative Care 2012;11. DOI: 10.1186/1472-684x-11-20.
25.
Merello M: Sialorrhoea and drooling in patients with Parkinson's disease. Drugs Aging 2008;25:1007-1019. DOI: 10.2165/0002512-200825120-00003.
26.
Leibner J, Ramjit A, Sedig L, Dai Y, Wu SS, Jacobson C, Fernandez HH: The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism Relat Disord 2010;16:475-477. DOI: 10.1016/j.parkreldis.2009.12.003.
27.
Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Driver-Dunckley E: Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord 2012;18:1089-1093. DOI: 10.1016/j.parkreldis.2012.06.008.
28.
Sitek EJ, Sołtan W, Wieczorek D, Robowski P, Sławek J: Self-awareness of memory function in Parkinson's disease in relation to mood and symptom severity. Aging Mental Health 2011;15:150-156. DOI: 10.1080/13607863.2010.508773.
29.
Karakis I, Cole AJ, Montouris GD, Luciano MS, Meador KJ, Piperidou C: Caregiver burden in epilepsy: determinants and impact. Epilepsy Res Treat 2014;2014:1-9. DOI: 10.1155/2014/808421.
30.
Werner P, Mittelman MS, Goldstein D, Heinik J: Family stigma and caregiver burden in Alzheimer's disease. Gerontologist 2011;52:89-97. DOI: 10.1093/geront/gnr117.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.